Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Projects Holdings, Inc.BSLK · Entity 65458 | Director | November 25, 2024 | November 27, 2024 |
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | Director | January 09, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Projects Holdings, Inc.
Report date November 25, 2024 · Filed November 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,500 |
Ending reported balance
After 2024-11-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-11-25 · Grant · Acquired 22,500 · Balance 57,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F2: Represents an award of RSUs, which vests in three equal annual installments commencing on August 13, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Row 2 · 2024-11-25 · Grant · Acquired 15,000 · Balance 72,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F3: Represents an award of RSUs, which vests in full on the earlier to occur of (i) August 13, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders following the grant date, subject to the Reporting Person's continued service on the Board through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.
F2: Represents an award of RSUs, which vests in three equal annual installments commencing on August 13, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
F3: Represents an award of RSUs, which vests in full on the earlier to occur of (i) August 13, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders following the grant date, subject to the Reporting Person's continued service on the Board through the applicable vesting date.
LISATA THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,815 |
Reported balance
After 2026-01-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 30,456 · Balance 95,815 F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2: Includes 30,456 unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027.
F2: Includes 30,456 unvested restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CAMBREX CORP
Report date December 04, 2019 · Filed December 05, 2019
Section 16 reporting ended · disclosed 2019-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-12-04 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2019-12-04 · Exercise / conversion · Acquired 50,000 · Balance 163,706 Row 2 · 2019-12-04 · Exercise / conversion · Acquired 50,000 · Balance 213,706 Row 3 · 2019-12-04 · Exercise / conversion · Acquired 38,000 · Balance 251,706 Row 4 · 2019-12-04 · Exercise / conversion · Acquired 30,000 · Balance 281,706 Row 5 · 2019-12-04 · Grant · Acquired 65,500 · Balance 347,206 F1: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration. Row 6 · 2019-12-04 · Sale · Disposed 347,206 · Balance 0 F2: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.36 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-12-04 · Exercise / conversion · Acquired 50,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.65 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-12-04 · Exercise / conversion · Acquired 50,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.64 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-12-04 · Exercise / conversion · Acquired 38,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.61 | Direct | 0 |
Reported balance
After 2019-12-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-12-04 · Exercise / conversion · Acquired 30,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration.
F2: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement.
F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:06 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 30,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001192621-26-000004 · wk-form4_1768338374.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,815 F1 · shares: Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. F2 · balance_after: Includes 30,456 unvested restricted stock units. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 15,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001192621-25-000002 · wk-form4_1736802432.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,359 F1 · shares: Represents 15,789 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2026. F2 · balance_after: Includes 15,789 unvested restricted stock units. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:30 UTC | Bolt Projects Holdings, Inc. BSLK · Entity 65458 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-103492 · ownership.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,500 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F3 · shares: Represents an award of RSUs, which vests in full on the earlier to occur of (i) August 13, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders following the grant date, subject to the Reporting Person's continued service on the Board through the applicable vesting date. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 21:30 UTC | Bolt Projects Holdings, Inc. BSLK · Entity 65458 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-103492 · ownership.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,500 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. F2 · shares: Represents an award of RSUs, which vests in three equal annual installments commencing on August 13, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:41 UTC | Bolt Projects Holdings, Inc. BSLK · Entity 65458 | Exercise / conversionClass B Common Stock · Derivative | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-069731 · ownership.xml · derivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On August 13, 2024, pursuant to that certain Business Combination Agreement, dated as of October 4, 2023, as amended, by and among the Golden Arrow Merger Corp., Beam Merger Sub, Inc. ("Merger Sub") and Bolt Threads, Inc. ("Old Bolt Threads"), Merger Sub merged with and into Old Bolt Threads with Old Bolt Threads surviving as a wholly owned subsidiary of Golden Arrow Merger Corp., which changed its name to Bolt Projects Holdings, Inc. (the "Merger"). Upon the completion of the Merger, the shares of Class B Common Stock issued by Old Bolt Threads were automatically converted into shares of the Issuer's Common Stock on a one-to-one basis. F1 · price: On August 13, 2024, pursuant to that certain Business Combination Agreement, dated as of October 4, 2023, as amended, by and among the Golden Arrow Merger Corp., Beam Merger Sub, Inc. ("Merger Sub") and Bolt Threads, Inc. ("Old Bolt Threads"), Merger Sub merged with and into Old Bolt Threads with Old Bolt Threads surviving as a wholly owned subsidiary of Golden Arrow Merger Corp., which changed its name to Bolt Projects Holdings, Inc. (the "Merger"). Upon the completion of the Merger, the shares of Class B Common Stock issued by Old Bolt Threads were automatically converted into shares of the Issuer's Common Stock on a one-to-one basis. F1 · derivative.exercise_date: On August 13, 2024, pursuant to that certain Business Combination Agreement, dated as of October 4, 2023, as amended, by and among the Golden Arrow Merger Corp., Beam Merger Sub, Inc. ("Merger Sub") and Bolt Threads, Inc. ("Old Bolt Threads"), Merger Sub merged with and into Old Bolt Threads with Old Bolt Threads surviving as a wholly owned subsidiary of Golden Arrow Merger Corp., which changed its name to Bolt Projects Holdings, Inc. (the "Merger"). Upon the completion of the Merger, the shares of Class B Common Stock issued by Old Bolt Threads were automatically converted into shares of the Issuer's Common Stock on a one-to-one basis. F1 · derivative.expiration_date: On August 13, 2024, pursuant to that certain Business Combination Agreement, dated as of October 4, 2023, as amended, by and among the Golden Arrow Merger Corp., Beam Merger Sub, Inc. ("Merger Sub") and Bolt Threads, Inc. ("Old Bolt Threads"), Merger Sub merged with and into Old Bolt Threads with Old Bolt Threads surviving as a wholly owned subsidiary of Golden Arrow Merger Corp., which changed its name to Bolt Projects Holdings, Inc. (the "Merger"). Upon the completion of the Merger, the shares of Class B Common Stock issued by Old Bolt Threads were automatically converted into shares of the Issuer's Common Stock on a one-to-one basis. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:41 UTC | Bolt Projects Holdings, Inc. BSLK · Entity 65458 | Exercise / conversionCommon Stock | 35,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-069731 · ownership.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 13, 2024, pursuant to that certain Business Combination Agreement, dated as of October 4, 2023, as amended, by and among the Golden Arrow Merger Corp., Beam Merger Sub, Inc. ("Merger Sub") and Bolt Threads, Inc. ("Old Bolt Threads"), Merger Sub merged with and into Old Bolt Threads with Old Bolt Threads surviving as a wholly owned subsidiary of Golden Arrow Merger Corp., which changed its name to Bolt Projects Holdings, Inc. (the "Merger"). Upon the completion of the Merger, the shares of Class B Common Stock issued by Old Bolt Threads were automatically converted into shares of the Issuer's Common Stock on a one-to-one basis. F1 · price: On August 13, 2024, pursuant to that certain Business Combination Agreement, dated as of October 4, 2023, as amended, by and among the Golden Arrow Merger Corp., Beam Merger Sub, Inc. ("Merger Sub") and Bolt Threads, Inc. ("Old Bolt Threads"), Merger Sub merged with and into Old Bolt Threads with Old Bolt Threads surviving as a wholly owned subsidiary of Golden Arrow Merger Corp., which changed its name to Bolt Projects Holdings, Inc. (the "Merger"). Upon the completion of the Merger, the shares of Class B Common Stock issued by Old Bolt Threads were automatically converted into shares of the Issuer's Common Stock on a one-to-one basis. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 19,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001192621-24-000003 · wk-form4_1705007305.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,570 F1 · shares: Represents 19,480 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2025. F2 · balance_after: Includes 19,480 unvested restricted stock units. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:18 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192621-23-000002 · wf-form4_167347191558820.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,090 F1 · shares: Represents 20,000 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2024. F2 · balance_after: Includes 24,362 unvested restricted stock units. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:12 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 65,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001192621-22-000002 · wf-form4_164202191754951.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,390 F1 · shares: Represents 65,430 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 10, 2023. F2 · balance_after: Includes 103,165 unvested restricted stock units. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:17 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 37,735 | $0.00 | $0.00 |
DisclosureSEC source: 0001192621-21-000003 · wf-form4_161049344702656.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,960 F1 · shares: Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022. F2 · balance_after: Includes 56,027 unvested restricted stock units. Read SEC document |
| January 13, 2020 Filed Jan 14, 2020 21:14 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 18,292 | $3.28 | $59,997.76 |
DisclosureSEC source: 0001192621-20-000002 · wf-form4_157903647697000.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,225 F1 · shares: Represents 18,292 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 13, 2021. F2 · balance_after: Includes 18,292 unvested restricted stock units. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $53.61 | $0.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · derivative · entry 10 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $45.64 | $0.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · derivative · entry 9 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $40.65 | $0.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · derivative · entry 8 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $41.36 | $0.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · derivative · entry 7 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 347,206 | $60.00 | $20,832,360.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · nonDerivative · entry 6 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 65,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · nonDerivative · entry 5 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,206 F1 · shares: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 30,000 | $53.61 | $1,608,150.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · nonDerivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 38,000 | $45.64 | $1,734,320.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 50,000 | $40.65 | $2,032,500.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:40 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 50,000 | $41.36 | $2,068,000.00 |
DisclosureSEC source: 0001209191-19-059247 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 17:05 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011177 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,706 F1 · shares: Pursuant to settlement of a performance share award. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 18:33 UTC | CAMBREX CORP CBM · Entity 153359 | GrantCommon Stock | 10,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007018 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,706 F1 · security: Represents Restricted Stock Units Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 21:04 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantRestricted Stock Units | 12,121 | $4.95 | $59,998.95 |
DisclosureSEC source: 0001192621-19-000013 · wf-form4_154767267234471.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,933 F1 · shares: Represents 12,121 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 14, 2020. F2 · balance_after: Includes 12,121 unvested restricted stock units. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 17:14 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 8,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001192621-19-000010 · wf-form4_154714047639341.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,812 F1 · shares: Represents 8,747 shares underlying restricted stock granted under the 2018 Equity Incentive Compensation Plan which were awarded on January 8, 2018 and which vested on January 8, 2019. Read SEC document |
| October 24, 2018 Filed Oct 26, 2018 16:10 UTC | CAMBREX CORP CBM · Entity 153359 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $53.61 | $0.00 |
DisclosureSEC source: 0001209191-18-056290 · doc4.xml · derivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2025-10-24 F1 · derivative.exercise_date: The option representing a right to purchase 30,000 shares becomes exercisable in four equal installments beginning October 24, 2019, which is the first anniversary of the date on which the option was granted. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 17:21 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001209191-18-056084 · doc4.xml · derivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 22, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 17:21 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 3,195 | $55.27 | $176,593.40 |
DisclosureSEC source: 0001209191-18-056084 · doc4.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.18 to $55.38 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 17:21 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 16,805 | $54.67 | $918,660.45 |
DisclosureSEC source: 0001209191-18-056084 · doc4.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,523 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.16 to $55.10 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| October 23, 2018 Filed Oct 24, 2018 17:21 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 20,000 | $17.81 | $356,200.00 |
DisclosureSEC source: 0001209191-18-056084 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001209191-18-049558 · doc4.xml · derivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 55,000 shares Expires 2021-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 22, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 25,809 | $66.83 | $1,724,815.47 |
DisclosureSEC source: 0001209191-18-049558 · doc4.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.50 to $67.30 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 29,191 | $65.84 | $1,921,935.44 |
DisclosureSEC source: 0001209191-18-049558 · doc4.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,137 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.425 to $66.35 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 16:24 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 55,000 | $17.81 | $979,550.00 |
DisclosureSEC source: 0001209191-18-049558 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 17:56 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 26,401 | $63.23 | $1,669,335.23 |
DisclosureSEC source: 0001209191-18-045748 · doc4.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,328 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.70 to $63.65 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| August 06, 2018 Filed Aug 7, 2018 17:56 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 53,599 | $62.07 | $3,326,889.93 |
DisclosureSEC source: 0001209191-18-045748 · doc4.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,729 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.65 to $62.65 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:34 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001209191-18-044967 · doc4.xml · derivative · entry 6 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 5,000 shares Expires 2021-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 22,2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:34 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-18-044967 · doc4.xml · derivative · entry 5 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2020-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 28,2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:34 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 22,782 | $62.78 | $1,430,222.07 |
DisclosureSEC source: 0001209191-18-044967 · doc4.xml · nonDerivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.70 to $62.95 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:34 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 32,218 | $62.23 | $2,005,026.02 |
DisclosureSEC source: 0001209191-18-044967 · doc4.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,110 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.70 to $62.675 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:34 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 5,000 | $17.81 | $89,050.00 |
DisclosureSEC source: 0001209191-18-044967 · doc4.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| August 01, 2018 Filed Aug 2, 2018 16:34 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 50,000 | $16.91 | $845,250.00 |
DisclosureSEC source: 0001209191-18-044967 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:20 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-18-041045 · doc4.xml · derivative · entry 6 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 30,000 shares Expires 2020-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 28,2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:20 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-18-041045 · doc4.xml · derivative · entry 5 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2019-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 24, 2013, which was the first anniversary of the date on which the option was granted. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:20 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 24,358 | $52.08 | $1,268,564.64 |
DisclosureSEC source: 0001209191-18-041045 · doc4.xml · nonDerivative · entry 4 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.35 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:20 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 30,642 | $51.45 | $1,576,530.90 |
DisclosureSEC source: 0001209191-18-041045 · doc4.xml · nonDerivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,686 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.975 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:20 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 30,000 | $16.91 | $507,150.00 |
DisclosureSEC source: 0001209191-18-041045 · doc4.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:20 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionCommon Stock | 25,000 | $12.46 | $311,500.00 |
DisclosureSEC source: 0001209191-18-041045 · doc4.xml · nonDerivative · entry 1 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 21:13 UTC | CAMBREX CORP CBM · Entity 153359 | Exercise / conversionStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-18-037357 · doc4.xml · derivative · entry 3 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 55,000 shares Expires 2019-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option representing a right to purchase 80,000 shares became exercisable in four equal installments beginning October 24, 2013 which was the first anniversary of the date on which the option was granted. Read SEC document |
| June 11, 2018 Filed Jun 12, 2018 21:13 UTC | CAMBREX CORP CBM · Entity 153359 | SaleCommon Stock | 55,000 | $45.64 | $2,510,244.00 |
DisclosureSEC source: 0001209191-18-037357 · doc4.xml · nonDerivative · entry 2 KLOSK STEVEN M · CIK 0001192621 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,328 F1 · shares: The exercise of stock options and sale of corresponding shares reported herein was carried out pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.40 to $45.95 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.